• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

静脉注射或门静脉注射中同种异体或同基因细胞的命运:门静脉注射诱导耐受机制的可能解释。

Fate of allogeneic or syngeneic cells in intravenous or portal vein injection: possible explanation for the mechanism of tolerance induction by portal vein injection.

作者信息

Zhang Y, Yasumizu R, Sugiura K, Hashimoto F, Amoh Y, Lian Z, Nishio N, Ikehara S

机构信息

First Department of Pathology, Kansai Medical University, Osaka, Japan.

出版信息

Eur J Immunol. 1994 Jul;24(7):1558-65. doi: 10.1002/eji.1830240716.

DOI:10.1002/eji.1830240716
PMID:7913037
Abstract

In this report we examine the fate of donor cells injected via different routes. When PKH-26-labeled C57BL/6 (B6) spleen cells were intravenously (i.v.) injected into BALB/c mice, the donor cells were rejected within 3 days. In contrast, when the same B6 spleen cells were portal venously (p.v.) injected, they were trapped in the recipient liver. When allogeneic or syngeneic whole bone marrow cells (BMC) or cells in a hemopoietic stem cell (HSC)-enriched fraction were either i.v. or p.v. injected, the cells accumulated in the liver. The cells trapped in the liver were found to be wheat germ agglutinin (WGA)-positive HSC. When B6 thymocytes were p.v. or i.v. injected into BALB/c mice, they were rapidly rejected. When BALB/c mice were i.v. preimmunized with unlabeled B6 spleen cells, BMC or thymocytes, the p.v. or i.v. injected PKH-26-labeled B6 spleen cells were rejected rapidly (within 2 days). In contrast, when BALB/c mice were p.v. preimmunized with B6 spleen cells or BMC, the p.v. or i.v. injected PKH-26-labeled B6 spleen cells were not rejected. The cells responsible for the tolerance induction were found to be HSC trapped in the liver. Delayed-type hypersensitivity assays revealed that the tolerance could be maintained for more than 49 days by p.v. injection plus i.v. injection (at intervals of 2 weeks) of HSC. These findings indicate that HSC trapped in the liver play a crucial role in the induction and maintenance of p.v. tolerance.

摘要

在本报告中,我们研究了通过不同途径注射的供体细胞的命运。当用PKH - 26标记的C57BL / 6(B6)脾细胞静脉内(i.v.)注射到BALB / c小鼠体内时,供体细胞在3天内被排斥。相比之下,当相同的B6脾细胞经门静脉(p.v.)注射时,它们被困在受体肝脏中。当同种异体或同基因的全骨髓细胞(BMC)或富含造血干细胞(HSC)的细胞组分经静脉内或门静脉内注射时,细胞在肝脏中积累。发现被困在肝脏中的细胞是小麦胚凝集素(WGA)阳性的HSC。当B6胸腺细胞经门静脉或静脉内注射到BALB / c小鼠体内时,它们会迅速被排斥。当用未标记的B6脾细胞、BMC或胸腺细胞对BALB / c小鼠进行静脉内预免疫时,经门静脉或静脉内注射的PKH - 26标记的B6脾细胞会迅速被排斥(在2天内)。相比之下,当用B6脾细胞或BMC对BALB / c小鼠进行门静脉内预免疫时,经门静脉或静脉内注射的PKH - 26标记的B6脾细胞不会被排斥。发现负责诱导耐受性的细胞是被困在肝脏中的HSC。迟发型超敏反应试验表明,通过门静脉内注射加静脉内注射(间隔2周)HSC,耐受性可维持超过49天。这些发现表明,被困在肝脏中的HSC在门静脉耐受性的诱导和维持中起关键作用。

相似文献

1
Fate of allogeneic or syngeneic cells in intravenous or portal vein injection: possible explanation for the mechanism of tolerance induction by portal vein injection.静脉注射或门静脉注射中同种异体或同基因细胞的命运:门静脉注射诱导耐受机制的可能解释。
Eur J Immunol. 1994 Jul;24(7):1558-65. doi: 10.1002/eji.1830240716.
2
Increased CD4+CD25+Foxp3+ regulatory T cells in tolerance induced by portal venous injection.门静脉注射诱导的耐受中CD4+CD25+Foxp3+调节性T细胞增加。
Surgery. 2009 Jun;145(6):663-74. doi: 10.1016/j.surg.2009.01.016. Epub 2009 Apr 19.
3
Studies on the induction of tolerance to alloantigens. I. The abrogation of potentials for delayed-type-hypersensitivity response to alloantigens by portal venous inoculation with allogeneic cells.同种异体抗原耐受性诱导的研究。I. 通过门静脉接种同种异体细胞消除对同种异体抗原的迟发型超敏反应潜能。
J Immunol. 1985 Jun;134(6):3656-61.
4
Induction of donor-specific T cell anergy by portal venous injection of allogeneic cells.通过门静脉注射同种异体细胞诱导供体特异性T细胞无能。
Immunobiology. 1997 Nov;197(5):460-77. doi: 10.1016/S0171-2985(97)80079-4.
5
Studies on the induction of tolerance to alloantigens. II. The generation of serum factor(s) able to transfer alloantigen-specific tolerance for delayed-type hypersensitivity by portal venous inoculation with allogeneic cells.同种抗原耐受性诱导的研究。II. 通过门静脉接种异基因细胞产生能够传递迟发型超敏反应同种抗原特异性耐受性的血清因子。
J Immunol. 1986 Apr 15;136(8):2763-8.
6
Studies on the induction of tolerance to alloantigens. III. Induction of antibodies directed against alloantigen-specific delayed-type hypersensitivity T cells by a single injection of allogeneic lymphocytes via portal venous route.同种异体抗原耐受性诱导的研究。III. 通过门静脉途径单次注射同种异体淋巴细胞诱导针对同种异体抗原特异性迟发型超敏反应T细胞的抗体。
J Immunol. 1988 Feb 1;140(3):717-22.
7
Successful allogeneic bone marrow transplantation (BMT) by injection of bone marrow cells via portal vein: stromal cells as BMT-facilitating cells.通过门静脉注射骨髓细胞成功进行同种异体骨髓移植:基质细胞作为促进骨髓移植的细胞。
Stem Cells. 2001;19(2):144-50. doi: 10.1634/stemcells.19-2-144.
8
Oral and portal venous tolerance in the interferon-gamma knockout (GKO) mouse.干扰素-γ基因敲除(GKO)小鼠的口服和门静脉耐受性
J Surg Res. 2004 Jun 15;119(2):107-12. doi: 10.1016/j.jss.2004.02.001.
9
Abrogation of the capacity of delayed-type hypersensitivity responses to alloantigens by intravenous injection of neuraminidase-treated allogeneic cells.通过静脉注射神经氨酸酶处理的同种异体细胞消除对同种异体抗原的迟发型超敏反应能力。
J Immunol. 1987 Dec 1;139(11):3652-9.
10
CD1-dependent natural killer (NK1.1(+)) T cells are required for oral and portal venous tolerance induction.依赖CD1的自然杀伤性(NK1.1(+))T细胞是诱导口服和门静脉耐受性所必需的。
J Surg Res. 2002 May 1;104(1):29-35. doi: 10.1006/jsre.2002.6400.

引用本文的文献

1
Comparison of the effect of bone marrow cells infusion through the portal vein and inferior vena cava combined with short-term rapamycin on allogeneic islet grafts in diabetic rats.门静脉和下腔静脉输注骨髓细胞联合短期雷帕霉素对糖尿病大鼠同种异体胰岛移植效果的比较
J Diabetes Investig. 2016 Jul;7(4):476-84. doi: 10.1111/jdi.12456. Epub 2016 Jan 23.
2
Bone marrow transplantation reverses new-onset immunoinflammatory diabetes in a mouse model.骨髓移植可逆转小鼠模型中的新发免疫炎症性糖尿病。
Int J Clin Exp Pathol. 2014 Jul 15;7(8):5327-36. eCollection 2014.
3
Simultaneous administration of a low-dose mixture of donor bone marrow cells and splenocytes plus adenovirus containing the CTLA4Ig gene result in stable mixed chimerism and long-term survival of cardiac allograft in rats.
同时给予低剂量供体骨髓细胞和脾细胞混合物以及含有CTLA4Ig基因的腺病毒,可导致大鼠心脏同种异体移植产生稳定的混合嵌合体并长期存活。
Immunology. 2003 Oct;110(2):275-86. doi: 10.1046/j.1365-2567.2003.01729.x.
4
New strategies for BMT and organ transplantation.骨髓移植和器官移植的新策略。
Int J Hematol. 2002 Aug;76 Suppl 1:161-4. doi: 10.1007/BF03165237.
5
A strategy for organ allografts without using immunosuppressants or irradiation.一种不使用免疫抑制剂或辐射的器官同种异体移植策略。
Proc Natl Acad Sci U S A. 1998 Jun 9;95(12):6947-52. doi: 10.1073/pnas.95.12.6947.
6
TAK-603 selectively suppresses Th1-type cytokine production and inhibits the progression of adjuvant arthritis.TAK-603选择性抑制Th1型细胞因子的产生并抑制佐剂性关节炎的进展。
Immunology. 1997 Sep;92(1):75-83. doi: 10.1046/j.1365-2567.1997.d01-2288.x.